Copanlisib Hydrochloride

盐酸可泮利塞

Report date: 2026/04/17 20:02:02
NME

Base Information

Drug NameCopanlisib Hydrochloride
Drug Alias NameCopanlisibum考泮利司可泮利塞Aliqopa奥罗巴® +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitorsPhosphatidylinositol 3 kinase alpha inhibitors
TargetsPhosphatidylinositol 3 kinase alphaPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsUterine Neoplasms +[22] 
Global Approved IndicationsLymphoma, Follicular
Approved Indications in ChinaLymphoma, Follicular
Original Approved Country/TerritoryUnited States
Original Approved Date2017/09/14
Country/TerritoryCzechiaBelgiumBulgaria +[49] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteBayer AGBayer Healthcare Pharmaceuticals Inc
Inactive CompaniesBayer Pharma AgBayer HealthcareH Lee Moffitt Cancer Center & Research Institute +[7] 
Active IndicationsSolid tumoursHematologic NeoplasmsMultiple Myeloma +[6] 
Inactive IndicationsEndometrial NeoplasmsUterine NeoplasmsGastrointestinal Neoplasms +[16] 

Other Information

ATC CodeL01EM02
Related LinksWikipediaKEGG